, Tracking Stock Market Picks
Enter Symbol:
Bio-Path Holdings Inc (BPTH) [hlAlert]

down 59.62 %

Bio-Path Holdings Inc (BPTH) rated Buy with price target $5 by Maxim Group

Posted on: Monday,  Jun 2, 2014  12:00 AM ET by Maxim Group

Maxim Group rated Buy Bio-Path Holdings Inc (NASDAQ: BPTH) on 06/02/2014. Previously Maxim Group rated Buy Bio-Path Holdings Inc (NASDAQ: BPTH) on
05/09/2014., when the stock price was $2.65. Since then, Bio-Path Holdings Inc has lost 59.62% as of 01/11/2016's recent price of $1.07.
If you would have followed the previous Maxim Group's recommendation on BPTH, you would have lost 59.62% of your investment in 612 days.

Bio-Path Holdings, Inc. is a development-stage company. The Company, through its wholly owned subsidiary, Bio-Path, Inc., is engaged in the business of financing and facilitating the development of cancer therapeutics. It has two exclusive licenses from The University of Texas M. D. Anderson Cancer Center for three lead products and nucleic acid delivery technology. These licenses specifically provide drug delivery platform technology with composition of matter intellectual property that enables systemic delivery of antisense, small interfering ribonucleic acid (RNA) (siRNA) and small molecules for treatment of cancer. BP-100-1.01 is the Company?s lead lipid delivery ribonucleic acid interference (RNAi) drug, which will be clinically tested for validation in acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous leukemia. BP-100-2.01 is the Company?s lead siRNA drug, which will be clinically tested for validation as a targeted ovarian cancer therapeutic agent.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/2/2014 12:00 AM Buy
2.71 5.00
as of 10/17/2014
1 Week up  16.19 %
1 Month up  5.17 %
3 Months down  -7.57 %
1 YTD down  -9.96 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/9/2014 12:00 AM Buy
2.65 5.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy